Literature DB >> 20546832

Efficacy of 7-valent pneumococcal conjugate vaccination in Germany: An analysis using the indirect cohort method.

Simon Rückinger1, Mark van der Linden, Ralf René Reinert, Rüdiger von Kries.   

Abstract

Efficacy of 7-valent pneumococcal conjugate vaccination has been shown in randomized controlled trials using 4 dose vaccination schedules in children under 2 years of age. A case-control study from the US showed considerable protection from IPD for reduced vaccination schedules and even some protection from only one dose. In Germany, delayed and incomplete vaccination is a major issue. We assessed efficacy of PCV7 using data on cases of IPD from active surveillance and applying the indirect cohort design proposed by Broome, comparing cases of IPD with a vaccine serotype with cases with a non-vaccine serotype. Efficacy of at least one dose of PCV7 was estimated to be 88.3% (95% CI: 64.0-96.6). Estimates of efficacy for one, two, and three doses in the first 7 months of life were 78.1% (3.4-96.1), 89.8% (20.6-100.0), and 94.6% (69.7-99.5) respectively. Our study adds to evidence of good protection from IPD by reduced vaccination schedules with PCV7, e.g. with two doses as primary series, in a setting where a high proportion of children receives vaccination delayed. Copyright 2010. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20546832     DOI: 10.1016/j.vaccine.2010.05.021

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  16 in total

1.  Indirect cohort analysis of 10-valent pneumococcal conjugate vaccine effectiveness against vaccine-type and vaccine-related invasive pneumococcal disease.

Authors:  Jennifer R Verani; Carla Magda A Santos Domingues; José Cassio de Moraes
Journal:  Vaccine       Date:  2015-10-24       Impact factor: 3.641

2.  The Use of Test-negative Controls to Monitor Vaccine Effectiveness: A Systematic Review of Methodology.

Authors:  Huiying Chua; Shuo Feng; Joseph A Lewnard; Sheena G Sullivan; Christopher C Blyth; Marc Lipsitch; Benjamin J Cowling
Journal:  Epidemiology       Date:  2020-01       Impact factor: 4.822

3.  Prediction of pneumococcal conjugate vaccine effectiveness against invasive pneumococcal disease using opsonophagocytic activity and antibody concentrations determined by enzyme-linked immunosorbent assay with 22F adsorption.

Authors:  L Schuerman; J Wysocki; J C Tejedor; M Knuf; K-H Kim; J Poolman
Journal:  Clin Vaccine Immunol       Date:  2011-10-12

4.  A cluster-randomised, non-inferiority trial of the impact of a two-dose compared to three-dose schedule of pneumococcal conjugate vaccination in rural Gambia: the PVS trial.

Authors:  Grant A Mackenzie; Isaac Osei; Rasheed Salaudeen; Ilias Hossain; Benjamin Young; Ousman Secka; Umberto D'Alessandro; Arto A Palmu; Jukka Jokinen; Jason Hinds; Stefan Flasche; Kim Mulholland; Cattram Nguyen; Brian Greenwood
Journal:  Trials       Date:  2022-01-24       Impact factor: 2.728

5.  Impact and effectiveness of a conjugate vaccine against invasive pneumococcal disease in Finland - a modelling approach.

Authors:  Hanna Rinta-Kokko; Markku Nurhonen; Kari Auranen
Journal:  Hum Vaccin Immunother       Date:  2020-12-17       Impact factor: 3.452

6.  Impact of routine PCV7 (Prevenar) vaccination of infants on the clinical and economic burden of pneumococcal disease in Malaysia.

Authors:  Syed Aljunid; Gulifeiya Abuduxike; Zafar Ahmed; Saperi Sulong; Amrizal Muhd Nur; Adrian Goh
Journal:  BMC Infect Dis       Date:  2011-09-21       Impact factor: 3.090

7.  Using the indirect cohort design to estimate the effectiveness of the seven valent pneumococcal conjugate vaccine in England and Wales.

Authors:  Nick Andrews; Pauline A Waight; Ray Borrow; Shamez Ladhani; Robert C George; Mary P E Slack; Elizabeth Miller
Journal:  PLoS One       Date:  2011-12-02       Impact factor: 3.240

8.  Higher levels of mucosal antibody to pneumococcal vaccine candidate proteins are associated with reduced acute otitis media caused by Streptococcus pneumoniae in young children.

Authors:  Q Xu; J R Casey; M E Pichichero
Journal:  Mucosal Immunol       Date:  2015-02-04       Impact factor: 7.313

9.  Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany.

Authors:  Mark van der Linden; Gerhard Falkenhorst; Stephanie Perniciaro; Matthias Imöhl
Journal:  PLoS One       Date:  2015-07-01       Impact factor: 3.240

10.  How is vaccine effectiveness scaled by the transmission dynamics of interacting pathogen strains with cross-protective immunity?

Authors:  Ryosuke Omori; Benjamin J Cowling; Hiroshi Nishiura
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.